Ultra-long acting Leverage Exavir’s focus on ultra-long-acting integrase inhibitors for HIV to target specialty pharma and payer partnerships seeking durable virology therapies and PrEP solutions, highlighting potential for reduced dosing frequency.

Niche CNS virology Position opportunities around central nervous system and virology nanomedicine collaborations, attracting biotech firms and contract development organizations seeking innovative delivery platforms for chronic disorders.

Early-stage traction With a small team and pre-revenue status, pursue strategic alliances with larger biopharma for co-development, licensing, or milestone-based partnerships that de-risk clinical progression while expanding rebuttal against competitors.

Lean funding runway Capitalize on recent $7M funding to approach grant-funded programs and non-dilutive financing channels, while tailoring outreach to investors and corporate partners interested in virology and CNS nanomedicine portfolios.

Competitive landscape Differentiate from peers by emphasizing nanomedicine platform advantages and ultra-long-acting profiles to target HIV therapies and PrEP, identifying collaboration routes with large-cap players and specialty vaccine or infectious disease units.